Lulu Wang

Lulu Wang

Gilead Sciences Inc. - California / United States
Engineering & Technology / Computer Science
AD Scientific Index ID: 4487145
-
person_outline Lulu Wang's MOST POPULAR ARTICLES
1-) GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver diseaseR Loomba, Z Kayali, M Noureddin, P Ruane, EJ Lawitz, M Bennett, ...Gastroenterology 155 (5), 1463-1473. e6, 20182262018
2-) Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trialsQM Anstee, EJ Lawitz, N Alkhouri, VWS Wong, M Romero‐Gomez, ...Hepatology 70 (5), 1521-1530, 20191622019
3-) Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trialsVWS Wong, WY Tak, GBB Goh, PN Cheng, EJ Lawitz, ZM Younossi, ...Clinical Gastroenterology and Hepatology, 202242022
4-) Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patientsEJ Lawitz, KW Li, E Nyangau, TJ Field, JC Chuang, A Billin, L Wang, ...Journal of lipid research 63 (9), 2022142022
5-) GS-0976, a liver-targeted acetyl-coa carboxylase (ACC) inhibitor, reduces plasma acylcarnitines in patients with nonalcoholic steatohepatitis (NASH)MR Charlton, M Lai, M Noureddin, JM Tarrant, L Wang, T Nguyen, ...Hepatology 68, 992A-993A, 201832018